This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Meta-analytic Integration of Case-Control Studies

MaryLou Mullen, RRT; Brian Mullen, PhD; Michael Carey, PhD

JAMA. 1993;270(15):1842-1845.

Abstract
Objectives.
—The purpose of this investigation was to provide an empirical summary of the evidence regarding the association between β-agonist use and death from asthma. This effort integrated the results of case-control studies that examined the use of β-agonists among asthmatic patients who died and the use of β-agonists among asthmatic patients who did not die. The possible moderating effects of patient sample age and mode of delivery (oral, metered-dose inhaler, and nebulizer) were also examined.

Data Sources.
—An on-line computer search (using MEDLINE) was conducted using the key words β-agonist and asthma. This search was supplemented by ancestry and descendency approach searches. Studies that were available as of April 1992 were eligible for inclusion in this integration.

Study Selection.
—Studies were included if they reported the precise numbers of cases and controls who did and did not use a β-agonist. A total of six case-control studies comprising 15 separate tests of the relation between β-agonist use and death from asthma and data for 364 cases and 1388 controls were included.

Data Extraction.
—The 2 (case vs control) x 2 (did vs did not use β-agonist) designs allowed for direct derivation of a ² statistic that tested the association between β-agonist use and death from asthma. Mode of delivery and average age of sample were also coded.

Data Synthesis.
—Statistical integration revealed a significant, although extremely weak, relation between β-agonist use and death from asthma (z=3.996; P=.000075; mean r=.055). This relation emerged only when β-agonists were administered with a nebulizer (z=4.481; P=.0000038; mean r=.103). There was no association between β-agonist use and death when β-agonists were administered by metered-dose inhaler (z=1.194; P=.11; mean r=.031) or orally (z=1.247; P=.1; mean r=.031). Adults were more likely than adolescents to evidence the association between β-agonist use and death.

Conclusions.
—These results document the extremely small magnitude of the relation between β-agonist use and death from asthma. Furthermore, these results specify that the weak relation between β-agonist use and death from asthma may really be restricted to the delivery of β-agonists with a nebulizer. These findings suggest that the headlines that followed the report by Spitzer et al (1992) were misleading.

(JAMA. 1993;270:1842-1845)

Author Affiliations
From the American Lung Association of Central New York (Ms Mullen), and the Department of Psychology, College of Liberal Arts & Sciences, Syracuse (NY) University (Drs Mullen and Carey).

Footnotes
The views expressed in this article represent those of the authors and do not represent the official positions of their organizations.

Reprint requests to the American Lung Association of Central New York, PO Box 6409, Syracuse, NY 13217-6409 (Ms Mullen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacotherapy of asthma: regular treatment or on demand?
Montuschi et al.
Ther Adv Respir Dis 2009;3:175-191.
ABSTRACT  

Regular Use of Corticosteroids and Low Use of Short-Acting {beta}2-Agonists Can Reduce Asthma Hospitalization
Senthilselvan et al.
Chest 2005;127:1242-1251.
ABSTRACT | FULL TEXT  

{beta}2-Agonists: Deja vu All Over Again : The Second-Generation Controversy
Bernstein
Chest 2002;122:763-765.
FULL TEXT  

Clinical trial end points: On the road to nowhere?
Holloway and Dick
Neurology 2002;58:679-686.
ABSTRACT | FULL TEXT  

The Management of Acute Severe Asthma
Kelly
Journal of Pharmacy Practice 2001;14:91-107.
ABSTRACT  

On demand use of {beta}2-agonists led to better asthma control than regular use in moderate to severe asthma
Quarton
Evid. Based Nurs. 2001;4:14-14.
FULL TEXT  

Safety of Over-the-Counter Inhalers for Asthma : Report of the Council on Scientific Affairs
Dickinson et al.
Chest 2000;118:522-526.
ABSTRACT | FULL TEXT  

Compliance With National Asthma Management Guidelines and Specialty Care: A Health Maintenance Organization Experience
Legorreta et al.
Arch Intern Med 1998;158:457-464.
ABSTRACT | FULL TEXT  

beta 2-Agonist Metered Dose Inhaler Overuse: Psychological and Demographic Profiles
Beausoleil et al.
Pediatrics 1997;99:40-43.
ABSTRACT | FULL TEXT  

Pulmonary and Critical Care Medicine
Pingleton
JAMA 1995;273:1717-1718.
ABSTRACT  

Controversies in Management: Adverse effects are not proved
Fuller
BMJ 1994;309:795-796.
FULL TEXT  

{beta}-Agonist Use and Death from Asthma
Alberg and Comstock
JAMA 1994;271:821-821.
ABSTRACT  

{beta}-Agonist Use and Death from Asthma-Reply
Mullen and Mullen
JAMA 1994;271:822-822.
ABSTRACT  

{beta}-Agonist Use and Death from Asthma
Suissa et al.
JAMA 1994;271:821-822.
ABSTRACT  

{beta}-Agonist Use and Death from Asthma
Pearce et al.
JAMA 1994;271:822-823.
ABSTRACT  

ASTHMA MORTALITY RISK FROM BETA-AGONISTS IS EXAGGERATED
JWatch General 1993;1993:1-1.
FULL TEXT